CORAL GABLES, Fla., April 23 /PRNewswire/ -- Stiefel Laboratories, Inc., today announced staff promotions and organizational changes that are part of its integration of operations into one global company. The changes, which establish a global commercial function for the company, come on the heels of Stiefel’s 2006 acquisition of Connetics Corporation.
Among the changes, the company has combined its U.S. Sales and Marketing teams; created a new Global Marketing team, which is responsible for marketing Stiefel Laboratories’ product portfolio globally and launching the former Connetics products around the world; and strengthened its Global Medical Affairs function, which facilitates collaboration and partnership between marketers and medical professionals at the company.
Charles Stiefel is Chief Executive Officer and Chairman of the Board of Stiefel Laboratories, the world’s largest independent pharmaceutical company specializing in dermatology. “This is an exciting time for Stiefel Laboratories,” he said. “The products, technology, and the expertise of employees in Palo Alto at the former Connetics Corp. expand our product portfolio. Our product development pipeline is complemented with potential products that will add depth to our offerings. This new structure and the proven team we have assembled will allow us to leverage global efficiencies, unify sales and marketing strategies, and strengthen the Stiefel Laboratories brand globally,” he said.
To lead this new team and achieve the company’s global objectives, Stiefel Laboratories has promoted Bill Humphries to the newly created position of Chief Commercial Officer. Humphries will be responsible for all Stiefel Laboratories sales, marketing, strategic communications, public relations, and other commercial aspects of the company’s global business.
Humphries, who helped oversee the Connetics merger, said he has been pleased with the process and outcomes. “We have integrated our people and our functions well, and I now look forward to the results that this team will provide for patients, physicians, and the employees of Stiefel Laboratories on a global basis,” Humphries said.
Other key staff promotions include:
- Richard J. MacKay has been appointed to Vice Chairman of the Board of Directors. In his new role, Mr. MacKay is charged with assessing the most important issues that face the company in a global context and assisting the Board and CEO on key projects and relationships. MacKay, who has been associated with Stiefel Laboratories and its products for more than 40 years, will retain the title of President, Stiefel Canada, Inc.
- The company announced in January 2007 that Pierre Boucher was promoted to Executive Vice President, responsible for day-to-day operations and strategic planning for Stiefel Canada.
- Jim Hartman has been promoted from Vice President of Stiefel U.S. Marketing to Senior Vice President, Stiefel U.S. Rx. Hartman will be responsible for the day-to-day commercial operations of the U.S. Rx business.
- Bresly Jaramillo has been promoted to Senior Vice President for Latin America and the Caribbean (LATAC). Bresly has led LATAC to three consecutive years of double-digit growth and has solidified Stiefel’s number one position in Brazil and Chile.
- Gabriel McGlynn will serve as Senior Vice President of EURASIA, which now includes the recently combined EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific) regions. McGlynn has more than 30 years experience in multicultural markets.
- Dr. Larry Staubach, Vice President for Global Medical Affairs, and his team will facilitate the collaboration and partnership between Stiefel marketers and Stiefel medical professionals.
- Alfonso Ugarte, Vice President of Global Marketing who joined Stiefel Laboratories in 2006 after 9 successful years with Merck & Co., will lead the team responsible for the globalization of the combined product portfolio, including the launch of the products from Connetics around the world.
- Luis Pena, Vice President for Global Portfolio Planning, formerly with Connetics, will be responsible for overseeing and leading the planning of the Global New Products Pipeline.
- Karen Cavanaugh, Vice President of the Global Steroid Responsive Dermatoses Franchise and New Product Planning, will be in charge of leading the development and marketing of the company’s combined Steroid Responsive Dermatoses portfolio worldwide. She will also lead the Commercial Operations Group in the development of new products.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is the world’s largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; Soriatane(R) (acitretin) capsules; Verdeso(TM) (desonide) Foam, 0.05%; Brevoxyl(R) Creamy Wash (benzoyl peroxide, 4% or 8%) packaged in the convenient new Brevoxyl Acne Wash Kit; Oilatum(R); and Sarna(R). Its wholly-owned global network is comprised of more than 30 subsidiaries (including the recently acquired Connetics), manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.
Stiefel Laboratories supplements its R&D efforts by aggressively seeking acquisitions of dermatological product lines and companies around the world. To learn more about Stiefel Laboratories, Inc., visit www.stiefel.com.
Stiefel Laboratories, Inc.
CONTACT: Denise Ulrich for Stiefel Laboratories, Inc.,dulrich@stiefel.com, +1-678-765-4104, cell, +1-770-656-9338
Web site: http://www.stiefel.com/
